Steel Therapeutics is developing FDA‑reviewable versions of commonly compounded therapies, beginning with Fizurex™, a single‑use medicated wipe targeting anal fissures. The Fizurex wipe incorporates a combination therapy currently compounded by pharmacists into a convenient single‑use format. Proceeds from the recent financing will be used to finalize Fizurex development, advance a preclinical testing program later this year, and support intellectual property protection. The company aims to submit its first IND to the FDA in 2023. Steel is led by Founder and CEO Matt Stahl, PharmD, and is based in North Liberty. The company recently closed a seed financing to position the program for clinical and regulatory steps.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

May 2022